Swiss Life Asset Management’s Denali Therapeutics DNLI Stock Holding History

Swiss Life Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Buy	+9,091	New	+$187K	﹤0.01%	1438

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Swiss Life Asset Management's DNLI Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 9,091 shares worth $234K. The stake represents ﹤0.01% of the portfolio and ranks #1438 among its holdings.

167 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Swiss Life Asset Management held 9,091 shares of Denali Therapeutics worth $234K as of Q2 2026.
Denali Therapeutics was a new Swiss Life Asset Management position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1438 holding.
167 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.